Clinical Trials

A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients

Condition:   Breast Cancer
Intervention:   Drug: Aromasin
Sponsor:   Pfizer
Terminated

Mon, 28 Feb 2011 12:00:00 EST

Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin

Condition:   Breast Neoplasms
Intervention:   Drug: Exemestane
Sponsor:   Pfizer
Completed

Fri, 03 Jul 2009 12:00:00 EDT

Exemestane in Advanced and Recurrent Endometrial Carcinoma

Condition:   Endometrial Cancer
Intervention:   Drug: Exemestane
Sponsor:   Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Completed

Fri, 18 Oct 2013 12:00:00 EDT

A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer

Condition:   Invasive Early Breast Cancer
Intervention:   Drug: Aromasin
Sponsor:   Pfizer
Terminated

Wed, 12 May 2010 12:00:00 EDT

Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer

Condition:   Breast Neoplasms
Intervention:   Drug: Aromasin
Sponsor:   Pfizer
Terminated

Thu, 11 Nov 2010 12:00:00 EST

Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD

Condition:   Breast Carcinoma
Intervention:   Drug: Exemestane
Sponsor:   National University Hospital, Singapore
Unknown status

Wed, 01 Aug 2012 12:00:00 EDT

An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin

Condition:   Breast Neoplasms
Intervention:   Other: Aromasin
Sponsor:   Pfizer
Terminated

Tue, 21 Oct 2008 12:00:00 EDT

Adjuvant Post-Tamoxifen Exemestane Trial

Condition:   Breast Cancer
Intervention:   Drug: exemestane
Sponsor:   Hellenic Breast Surgeons Society
Terminated

Thu, 18 Dec 2008 12:00:00 EST

Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients

Condition:   Early Breast Cancer
Intervention:   Other: Aromasin (exemestane)
Sponsor:   Pfizer
Terminated

Thu, 01 Jul 2010 12:00:00 EDT

Exemestane in Post-Menopausal Women With NSCLC

Condition:   Non-Small Cell Lung Cancer
Intervention:   Drug: Exemestane
Sponsor:   Masonic Cancer Center, University of Minnesota
Recruiting

Thu, 28 Jan 2016 12:00:00 EST

Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane

Condition:   Breast Neoplasms
Interventions:   Drug: exemestane (Aromasin);   Drug: tamoxifen + exemestane
Sponsor:   Pfizer
Completed

Thu, 09 May 2002 12:00:00 EDT

Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy Subjects

Condition:   Healthy
Interventions:   Drug: Reference product (A) Aromasin (Exemestane);   Drug: Test product (B) Exemestane
Sponsor:   Actavis Inc.
Withdrawn

Fri, 04 Jan 2013 12:00:00 EST

Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

Condition:   Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions:   Drug: Exemestane;   Drug: Everolimus
Sponsor:   Organisation for Oncology and Translational Research
Unknown status

Wed, 01 Jan 2014 12:00:00 EST

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Aromasin
Sponsor:   Pfizer
Completed

Tue, 12 Jan 2010 12:00:00 EST

Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Exemestane;   Drug: Sutent
Sponsors:   Baylor Breast Care Center;   Pfizer
Terminated

Wed, 20 May 2009 12:00:00 EDT

Exemestane and Cyclophosphamide for Metastatic Breast Cancer

Condition:   Metastatic Beast Cancer
Interventions:   Drug: Exemestane;   Drug: Cyclophosphamide
Sponsor:   NYU Langone Health
Completed

Wed, 16 Oct 2013 12:00:00 EDT

Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Exemestane
Sponsor:   Tianjin Medical University
Unknown status

Tue, 24 Jul 2012 12:00:00 EDT

Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions

Condition:   Breast Cancer
Intervention:   Drug: exemestane
Sponsor:   Roxane Laboratories
Completed

Fri, 08 Apr 2011 12:00:00 EDT

Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions

Condition:   Breast Cancer
Intervention:   Drug: exemestane
Sponsor:   Roxane Laboratories
Completed

Fri, 08 Apr 2011 12:00:00 EDT

Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions

Condition:   Breast Cancer
Intervention:   Drug: exemestane
Sponsor:   Roxane Laboratories
Completed

Fri, 08 Apr 2011 12:00:00 EDT

Exemestane and Celecoxib in Postmenopausal Women at High Risk for Breast Cancer

Condition:   Breast Neoplasms
Interventions:   Drug: Exemestane;   Dietary Supplement: Calcium carbonate;   Dietary Supplement: Vitamin D
Sponsors:   Georgetown University;   National Cancer Institute (NCI)
Completed

Mon, 17 Nov 2003 12:00:00 EST

Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer

Conditions:   Breast Cancer;   Estrogen Receptor-Positive Breast Cancer;   Breast Cancer, Estrogen Receptor-Positive;   ER+ Breast Cancer
Interventions:   Drug: entinostat;   Drug: exemestane;   Drug: Placebo
Sponsor:   Syndax Pharmaceuticals
Completed

Tue, 13 May 2008 12:00:00 EDT

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

Condition:   Breast Neoplasms
Interventions:   Drug: Exemestane;   Drug: Celecoxib + Exemestane
Sponsor:   Pfizer
Completed

Thu, 30 May 2002 12:00:00 EDT

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

Condition:   Breast Cancer
Interventions:   Drug: BIIB021;   Drug: exemestane (Aromasin)
Sponsor:   Biogen
Completed

Thu, 29 Oct 2009 12:00:00 EDT

Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China

Condition:   Breast Neoplasms
Intervention:   Drug: Aromasin (exemestane)
Sponsor:   Pfizer
Completed

Fri, 06 Aug 2010 12:00:00 EDT

Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST)

Condition:   Post Menopausal Women With Early Breast Cancer
Intervention:   Drug: Aromasin (exemestane)
Sponsor:   Pfizer
Completed

Fri, 15 Jan 2010 12:00:00 EST

Exemestane-RAD001-Metformin

Condition:   Breast Cancer
Interventions:   Drug: Everolimus;   Drug: Exemestane;   Drug: Metformin
Sponsors:   M.D. Anderson Cancer Center;   Susan G. Komen Breast Cancer Foundation
Terminated

Mon, 25 Jun 2012 12:00:00 EDT

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Condition:   Her2 Negative Breast Cancer Patients
Interventions:   Drug: MM-121;   Drug: Placebo;   Drug: Exemestane
Sponsor:   Merrimack Pharmaceuticals
Completed

Fri, 25 Jun 2010 12:00:00 EDT

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Enzalutamide;   Drug: exemestane;   Drug: Placebo (for enzalutamide)
Sponsors:   Pfizer;   Astellas Pharma Inc;   Medivation, Inc.
Active, not recruiting

Tue, 10 Dec 2013 12:00:00 EST

Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Megestrol acetate;   Drug: exemestane (Aromasin)
Sponsor:   Pfizer
Completed

Tue, 09 Nov 2010 12:00:00 EST

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

Conditions:   Atypical Hyperplasia;   Endometrial Atypical Hyperplasia /Endometrioid Intraepithelial Neoplasia;   FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma;   FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Interventions:   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Other: Pharmacokinetic Study;   Other: Questionnaire Administration
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Tue, 03 Oct 2017 12:00:00 EDT

Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer

Condition:   Ovarian Cancer
Interventions:   Drug: Exemestane;   Other: Placebo oral tablet
Sponsors:   Ente Ospedaliero Ospedali Galliera;   Istituto Di Ricerche Farmacologiche Mario Negri;   Fondazione Policlinico Universitario Agostino Gemelli IRCCS;   Federation of Italian Cooperative Oncology Groups
Recruiting

Wed, 08 Jul 2020 12:00:00 EDT

A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)

Condition:   Breast Neoplasms
Interventions:   Drug: Ridaforolimus;   Drug: Dalotuzumab;   Drug: Exemestane
Sponsor:   Merck Sharp & Dohme Corp.
Completed

Thu, 24 May 2012 12:00:00 EDT

Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Chidamide;   Drug: exemestane;   Drug: placebo
Sponsor:   Chipscreen Biosciences, Ltd.
Active, not recruiting

Fri, 26 Jun 2015 12:00:00 EDT

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

Conditions:   Locally Advanced Breast Cancer;   Metastatic Breast Cancer
Interventions:   Drug: Fulvestrant;   Drug: Exemestane
Sponsor:   AstraZeneca
Completed

Wed, 23 Jul 2003 12:00:00 EDT


Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer

Conditions:   Breast Cancer;   Estrogen Receptor Positive Breast Cancer
Interventions:   Drug: entinostat;   Drug: exemestane
Sponsor:   Syndax Pharmaceuticals
Unknown status

Fri, 01 Jul 2016 12:00:00 EDT

Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Exemestane;   Drug: Celecoxib;   Other: Correlative studies
Sponsors:   Ohio State University Comprehensive Cancer Center;   Pfizer
Completed

Tue, 20 Sep 2005 12:00:00 EDT

Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Exemestane;   Drug: Fulvestrant
Sponsors:   Ohio State University Comprehensive Cancer Center;   Pfizer
Completed

Tue, 20 Sep 2005 12:00:00 EDT

GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

Condition:   Advanced Estrogen Receptor Positive HER2- Breast Cancer
Interventions:   Drug: GS-5829;   Drug: Exemestane;   Drug: Fulvestrant
Sponsor:   Gilead Sciences
Terminated

Tue, 06 Dec 2016 12:00:00 EST

Exemestane + Celecoxib vs Exemestane + Placebo in Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: placebo;   Drug: Celecoxib;   Drug: Exemestane
Sponsor:   ARCAGY/ GINECO GROUP
Completed

Wed, 05 Sep 2007 12:00:00 EDT

Exemestane (Aromasine) + Tamoxifen - Breast Neo-Adjuvant

Condition:   Breast Neoplasms
Interventions:   Drug: Exemestane;   Drug: tamoxifen
Sponsors:   Institut Claudius Regaud;   PHARMACIA SAS
Completed

Fri, 12 Jun 2009 12:00:00 EDT

Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer

Condition:   Premenopausal Breast Cancer
Intervention:   Drug: Pembrolizumab/ Exemestane/ Leuprolide
Sponsors:   National Taiwan University Hospital;   Merck Sharp & Dohme Corp.
Recruiting

Tue, 13 Dec 2016 12:00:00 EST

Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer

Condition:   Breast Neoplasms
Interventions:   Drug: exemestane;   Drug: tamoxifen
Sponsor:   Pfizer
Completed

Thu, 19 Jan 2006 12:00:00 EST

Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer

Condition:   Breast Neoplasms
Interventions:   Drug: PF-04691502;   Drug: Exemestane
Sponsor:   Pfizer
Withdrawn

Mon, 06 Aug 2012 12:00:00 EDT

An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis

Condition:   Oestrogen Receptor Positive Advanced Breast Cancer
Interventions:   Drug: RAD001;   Drug: Exemestane
Sponsor:   Novartis Pharmaceuticals
Completed

Thu, 06 Dec 2012 12:00:00 EST

Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients

Condition:   Breast Cancer
Interventions:   Drug: Exemestane;   Drug: Anastrozole
Sponsors:   Spanish Breast Cancer Research Group;   Pfizer
Completed

Wed, 10 Aug 2005 12:00:00 EDT

Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer

Condition:   Breast Neoplasms
Interventions:   Drug: aspirin;   Drug: Exemestane
Sponsor:   Chinese Academy of Medical Sciences
Unknown status

Fri, 09 Sep 2011 12:00:00 EDT

Neoadjuvant Tucidinostat and Exemestane in Early Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Tucidinostat;   Drug: Exemestane;   Drug: Ovarian function suppression
Sponsor:   First Affiliated Hospital, Sun Yat-Sen University
Recruiting

Thu, 09 Jul 2020 12:00:00 EDT

Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients

Condition:   Breast Cancer
Interventions:   Drug: Fulvestrant 500 mg;   Drug: Exemestane 25 mg
Sponsors:   Chinese Academy of Medical Sciences;   Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Unknown status

Wed, 06 Jan 2016 12:00:00 EST

Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer

Conditions:   Stage 0 Breast Cancer AJCC v6 and v7;   Stage I Breast Cancer AJCC v7;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage II Breast Cancer AJCC v6 and v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7
Interventions:   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Placebo Administration;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Procedure: Therapeutic Conventional Surgery
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Fri, 06 Nov 2015 12:00:00 EST

Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane

Conditions:   Hormone Receptor Positive Malignant Neoplasm of Breast;   Metastatic Breast Cancer
Intervention:   Drug: Everolimus plus Exemestane
Sponsors:   VU University Medical Center;   Borstkanker Onderzoek Groep;   Novartis
Unknown status

Thu, 10 Apr 2014 12:00:00 EDT

A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor

Condition:   Advanced Breast Cancer
Interventions:   Drug: Everolimus;   Drug: Exemestane;   Drug: Everolimus Placebo
Sponsor:   Novartis Pharmaceuticals
Active, not recruiting

Wed, 18 Oct 2017 12:00:00 EDT

Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer

Condition:   Advanced Breast Cancer
Interventions:   Drug: Entinostat;   Drug: Placebo;   Drug: Exemestane
Sponsor:   Taizhou EOC Pharma Co., Ltd.
Active, not recruiting

Tue, 29 May 2018 12:00:00 EDT

Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers

Condition:   Breast Cancer
Interventions:   Drug: Exemestane;   Drug: Docetaxel;   Drug: Cytoxan
Sponsors:   Emory University;   Pfizer
Completed

Fri, 17 Jul 2009 12:00:00 EDT

Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer

Condition:   Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
Intervention:   Drug: palbociclib and exemestane plus trastuzumab and pyrotinib
Sponsor:   Guangdong Provincial People's Hospital
Not yet recruiting

Mon, 26 Apr 2021 12:00:00 EDT

Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: Placebo
Sponsor:   NCIC Clinical Trials Group
Completed

Thu, 07 Aug 2003 12:00:00 EDT

Exemestane With or Without Bicalutamide in Treating Patients With Stage IV Prostate Cancer

Condition:   Prostate Cancer
Interventions:   Drug: Exemestane;   Drug: Exemestane+bicalutamide
Sponsor:   Swiss Group for Clinical Cancer Research
Completed

Tue, 01 Jul 2003 12:00:00 EDT

Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: exemestane
Sponsors:   NCIC Clinical Trials Group;   Grupo Espanol de Investigacion del Cancer de Mama;   UNICANCER
Completed

Mon, 17 May 2004 12:00:00 EDT

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

Condition:   Breast Cancer
Interventions:   Drug: Everolimus;   Drug: Exemestane;   Drug: Everolimus Placebo
Sponsor:   Novartis Pharmaceuticals
Completed

Wed, 18 Mar 2009 12:00:00 EDT

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer

Conditions:   Metastatic Breast Cancer;   Breast Cancer;   Hormone Receptor Positive Tumor;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Locally Advanced Malignant Neoplasm
Interventions:   Drug: Everolimus;   Drug: Exemestane;   Drug: Fulvestrant
Sponsors:   Consorzio Oncotech;   Clinical Research Technology S.r.l.
Unknown status

Tue, 31 Mar 2015 12:00:00 EDT

Aromasin (Exemestane) in Patients With Recurrent or Refractory Stage II - IV Epithelial Ovarian Cancer

Condition:   Ovarian Cancer
Intervention:   Drug: Exemestane
Sponsor:   Ottawa Hospital Research Institute
Completed

Fri, 02 Dec 2005 12:00:00 EST

The Impact of Obesity and Obesity Treatments on Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Exemestane;   Drug: Avandamet
Sponsors:   M.D. Anderson Cancer Center;   Susan G. Komen Breast Cancer Foundation
Completed

Tue, 07 Jul 2009 12:00:00 EDT

Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors

Conditions:   Neoplasms;   Breast Neoplasms;   Kidney Neoplasms;   Pancreatic Neuroendocine Neoplasms (pNETs)
Interventions:   Drug: alpelisib;   Drug: everolimus;   Drug: exemestane
Sponsor:   Novartis Pharmaceuticals
Completed

Tue, 04 Mar 2014 12:00:00 EST

Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

Condition:   Breast Neoplasms
Intervention:   Drug: exemestane (Aromasin®)
Sponsor:   Pfizer
Completed

Thu, 15 Sep 2005 12:00:00 EDT

Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer

Condition:   Breast Neoplasms
Interventions:   Drug: exemestane;   Drug: anastrozole
Sponsor:   Pfizer
Completed

Fri, 02 Sep 2005 12:00:00 EDT

Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women

Condition:   Breast Neoplasms
Intervention:   Drug: exemestane
Sponsor:   Pfizer
Terminated

Thu, 20 Jun 2002 12:00:00 EDT

Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors

Conditions:   Breast Cancer;   Stage II Breast Cancer;   Stage III Breast Cancer
Interventions:   Drug: Exemestane;   Drug: Exemestane and tamoxifen
Sponsor:   University of Colorado, Denver
Active, not recruiting

Mon, 15 Apr 2013 12:00:00 EDT

Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

Condition:   Advanced Breast Cancer
Interventions:   Drug: Bosutinib;   Drug: exemestane;   Drug: Exemestane
Sponsor:   Pfizer
Terminated

Wed, 19 Nov 2008 12:00:00 EST

Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Everolimus and exemestane
Sponsor:   Novartis Healthcare A/S
Completed

Mon, 30 Dec 2013 12:00:00 EST

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: exemestane
Sponsors:   NCIC Clinical Trials Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   Cancer and Leukemia Group B;   Eastern Cooperative Oncology Group;   Southwest Oncology Group;   International Breast Cancer Study Group
Completed

Thu, 07 Aug 2003 12:00:00 EDT

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

Conditions:   Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions:   Drug: Exemestane;   Drug: Gamma-Secretase Inhibitor RO4929097;   Drug: Goserelin Acetate
Sponsor:   National Cancer Institute (NCI)
Terminated

Wed, 23 Jun 2010 12:00:00 EDT

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

Condition:   Solid Tumors and Lymphomas
Interventions:   Drug: Alobresib;   Drug: Exemestane;   Drug: Fulvestrant
Sponsor:   Gilead Sciences
Completed

Thu, 19 Mar 2015 12:00:00 EDT

Palbociclib With Everolimus + Exemestane In BC

Conditions:   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Hormone Receptor (HR)-Positive Breast Cancer
Interventions:   Drug: Palbociclib;   Drug: Everolimus;   Drug: Exemestane
Sponsors:   Dana-Farber Cancer Institute;   Pfizer
Active, not recruiting

Thu, 18 Aug 2016 12:00:00 EDT

Exemestane in Treating Postmenopausal Women With Stage IV Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: immunohistochemistry staining method
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
Completed

Thu, 18 Dec 2008 12:00:00 EST

Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Exemestane + Dasatinib;   Drug: Exemestane + Placebo
Sponsor:   Bristol-Myers Squibb
Completed

Tue, 07 Oct 2008 12:00:00 EDT

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

Condition:   Breast Neoplasms
Interventions:   Drug: exemestane;   Drug: sunitinib malate
Sponsor:   Pfizer
Terminated

Thu, 04 Jan 2007 12:00:00 EST

Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women

Condition:   Breast Cancer
Interventions:   Drug: Everolimus;   Drug: Exemestane
Sponsors:   Jules Bordet Institute;   Novartis
Unknown status

Tue, 07 Jan 2014 12:00:00 EST

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: tamoxifen;   Drug: triptorelin
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Breast International Group
Active, not recruiting

Thu, 07 Aug 2003 12:00:00 EDT

Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)

Condition:   Progression-free Survival
Interventions:   Drug: fulvestrant;   Drug: anastrozole;   Drug: exemestane
Sponsor:   AstraZeneca
Completed

Thu, 23 Jul 2009 12:00:00 EDT

Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer

Conditions:   Primary Breast Cancer ER+ve;   Primary Breast Cancer AR+ve TNBN
Interventions:   Drug: Enzalutamide;   Drug: Exemestane
Sponsors:   Queen Mary University of London;   Astellas Pharma Inc
Active, not recruiting

Tue, 09 Feb 2016 12:00:00 EST

BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer

Condition:   Metastatic or Locally-advanced Unresectable Breast Cancer
Interventions:   Drug: BYL719;   Drug: Letrozole;   Drug: Exemestane
Sponsors:   Memorial Sloan Kettering Cancer Center;   Novartis Pharmaceuticals
Active, not recruiting

Thu, 06 Jun 2013 12:00:00 EDT

Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Condition:   Post Menopausal Breast Cancer
Interventions:   Drug: everolimus;   Drug: exemestane
Sponsor:   Novartis Pharmaceuticals
Completed

Mon, 05 Jun 2017 12:00:00 EDT

Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer

Condition:   Breast Neoplasms
Interventions:   Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Placebo (saline);   Drug: Exemestane;   Drug: Everolimus
Sponsor:   Bayer
Active, not recruiting

Tue, 07 Oct 2014 12:00:00 EDT

A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.

Condition:   Breast Cancer
Interventions:   Drug: Capecitabine;   Drug: Exemestane;   Drug: Everolimus
Sponsor:   Novartis Pharmaceuticals
Completed

Tue, 05 Feb 2013 12:00:00 EST

Combined Estrogen Blockade of the Breast With Exemestane and Raloxifene in Postmenopausal Women With a History of Breast Cancer Who Have No Clinical Evidence of Disease

Condition:   Breast Cancer
Interventions:   Drug: Raloxifene followed by combination therapy;   Drug: Exemestane followed by combination therapy
Sponsors:   Memorial Sloan Kettering Cancer Center;   Pharmacia
Completed

Tue, 20 Sep 2005 12:00:00 EDT

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Condition:   Hormone-receptor Positive Breast Cancer
Intervention:   Drug: exemestane and pazopanib
Sponsor:   GlaxoSmithKline
Withdrawn

Thu, 14 Feb 2008 12:00:00 EST

Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: Placebo
Sponsors:   NSABP Foundation Inc;   National Cancer Institute (NCI)
Completed

Mon, 27 Jan 2003 12:00:00 EST

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Exemestane;   Drug: Everolimus (RAD001)
Sponsor:   Novartis Pharmaceuticals
Completed

Fri, 22 Jun 2012 12:00:00 EDT

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: ribociclib (LEE011);   Drug: Exemestane;   Drug: Everolimus (RAD001)
Sponsor:   Novartis Pharmaceuticals
Completed

Mon, 20 May 2013 12:00:00 EDT

1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer

Condition:   First Line Metastatic Breast Cancer
Interventions:   Drug: Paclitaxel;   Drug: Bevacizumab;   Drug: Exemestane
Sponsor:   ARCAGY/ GINECO GROUP
Terminated

Fri, 25 Feb 2011 12:00:00 EST

A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Palbociclib;   Drug: Exemestane;   Drug: Leuprolide Acetate;   Drug: Capecitabine
Sponsor:   Samsung Medical Center
Unknown status

Fri, 30 Oct 2015 12:00:00 EDT

Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer

Condition:   Stage IV Non-small Cell Lung Cancer
Interventions:   Drug: exemestane;   Drug: pemetrexed disodium;   Drug: carboplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Other: questionnaire administration;   Procedure: quality-of-life assessment
Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed

Tue, 14 Aug 2012 12:00:00 EDT

A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Conditions:   Metastatic ER+ Her2- Breast Cancer;   Postmenopausal
Interventions:   Drug: Exemestane;   Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane;   Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsor:   Janssen Research & Development, LLC
Completed

Mon, 27 Jun 2011 12:00:00 EDT

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Condition:   Breast Neoplasms
Interventions:   Drug: CP-751,871;   Drug: exemestane;   Drug: Fulvestrant
Sponsor:   Pfizer
Terminated

Thu, 07 Sep 2006 12:00:00 EDT

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Sapanisertib;   Drug: Fulvestrant;   Drug: Exemestane
Sponsor:   Millennium Pharmaceuticals, Inc.
Completed

Thu, 30 Jan 2014 12:00:00 EST

Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: KHK2375;   Drug: Exemestane
Sponsor:   Kyowa Kirin Co., Ltd.
Active, not recruiting

Tue, 08 Dec 2015 12:00:00 EST

Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer

Condition:   Breast Neoplasms
Interventions:   Drug: Tamoxifen;   Drug: Exemestane
Sponsors:   Pfizer;   International Collaborative Cancer Group
Completed

Mon, 03 Jun 2002 12:00:00 EDT

A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors

Condition:   Advanced Breast Cancer
Interventions:   Drug: LXI-15029;   Drug: LXI-15029+Exemestane
Sponsor:   Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Recruiting

Mon, 24 Apr 2017 12:00:00 EDT

Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.

Condition:   Breast Cancer
Interventions:   Drug: Ribociclib;   Drug: Everolimus;   Drug: Exemestane
Sponsor:   Novartis Pharmaceuticals
Completed

Fri, 08 Apr 2016 12:00:00 EDT

Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: letrozole;   Drug: exemestane
Sponsor:   Fudan University
Unknown status

Fri, 15 May 2009 12:00:00 EDT

Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer

Conditions:   Estrogen Receptor-positive Breast Cancer;   Progesterone Receptor Positive Tumor;   Recurrent Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions:   Biological: therapeutic estradiol;   Drug: exemestane;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay
Sponsors:   University of Arizona;   National Cancer Institute (NCI)
Completed

Thu, 30 Jun 2011 12:00:00 EDT

Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: sunitinib malate;   Other: placebo
Sponsor:   Institut Català d'Oncologia
Unknown status

Thu, 02 Jul 2009 12:00:00 EDT

The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread

Condition:   Breast Neoplasms
Interventions:   Drug: Xentuzumab;   Drug: Placebo;   Drug: Everolimus;   Drug: Exemestane
Sponsor:   Boehringer Ingelheim
Active, not recruiting

Thu, 06 Sep 2018 12:00:00 EDT

A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations (STEP)

Condition:   CYP2D6 Polymorphism
Interventions:   Drug: Exemestane Tablets;   Other: ovarian function suppression/ablation;   Genetic: CYP2D6*10 gene test;   Drug: Tamoxifen
Sponsors:   Cancer Institute and Hospital, Chinese Academy of Medical Sciences;   Pfizer
Enrolling by invitation

Tue, 02 May 2017 12:00:00 EDT

BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors

Condition:   Neoplasms
Interventions:   Drug: BI 860585;   Drug: exemestane;   Drug: paclitaxel
Sponsor:   Boehringer Ingelheim
Completed

Tue, 10 Sep 2013 12:00:00 EDT

ELBA: Exemestane and Lapatinib in Advanced Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: lapatinib
Sponsor:   National Cancer Institute, Naples
Withdrawn

Sun, 01 Nov 2009 12:00:00 EDT

Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: goserelin acetate
Sponsors:   NYU Langone Health;   National Cancer Institute (NCI)
Completed

Wed, 21 Apr 2004 12:00:00 EDT

500mg Fulvestrant Versus Exemestane in MBC

Condition:   Breast Cancer
Intervention:  
Sponsor:   Fudan University
Completed

Mon, 02 Jul 2018 12:00:00 EDT

QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

Conditions:   Breast Cancer;   Breast Tumors;   Metastatic Cancer
Intervention:   Drug: AMG 479 or placebo administered with either exemestane or fulvestrant
Sponsor:   NantCell, Inc.
Completed

Fri, 29 Feb 2008 12:00:00 EST

Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: tamoxifen citrate
Sponsors:   International Collaborative Cancer Group;   European Organisation for Research and Treatment of Cancer - EORTC;   UNICANCER
Unknown status

Fri, 23 Jan 2004 12:00:00 EST

Exemestane Compared With Tamoxifen in Treating Women With Locally Recurrent or Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: tamoxifen citrate
Sponsor:   European Organisation for Research and Treatment of Cancer - EORTC
Completed

Fri, 11 Apr 2003 12:00:00 EDT

PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Palbociclib;   Drug: Exemestane;   Drug: Goserelin
Sponsor:   Hamdy A. Azim
Recruiting

Wed, 28 Sep 2016 12:00:00 EDT

Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer

Condition:   Breast Cancer
Interventions:   Biological: trastuzumab;   Drug: exemestane
Sponsors:   Northwestern University;   National Cancer Institute (NCI)
Withdrawn

Wed, 09 Apr 2003 12:00:00 EDT

Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients

Condition:   Breast Cancer
Interventions:   Drug: OFS + Anastrozole;   Drug: OFS + Exemestane
Sponsor:   Shanghai Jiao Tong University School of Medicine
Recruiting

Tue, 12 May 2015 12:00:00 EDT

Ruxolitinib in Estrogen Receptor Positive Breast Cancer

Condition:   Estrogen-receptor Positive Invasive Metastatic Breast Cancer
Interventions:   Drug: Ruxolitinib;   Drug: Exemestane
Sponsor:   Abramson Cancer Center of the University of Pennsylvania
Completed

Wed, 09 May 2012 12:00:00 EDT

Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients

Condition:   Male Breast Cancer
Interventions:   Drug: Tamoxifen;   Drug: Tamoxifen and GnRH analogue;   Drug: Exemestane and GnRH analogue
Sponsors:   German Breast Group;   Pfizer
Completed

Wed, 11 Jul 2012 12:00:00 EDT

Metabolizing Enzyme Genotype Versus Exemestane Metabolism Profiles

Condition:   Breast Cancer
Intervention:  
Sponsor:   Milton S. Hershey Medical Center
Completed

Fri, 22 Jun 2012 12:00:00 EDT

Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Entinostat;   Drug: Exemestane
Sponsor:   Taizhou EOC Pharma Co., Ltd.
Completed

Thu, 14 Jul 2016 12:00:00 EDT

Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Palbociclib;   Drug: Capecitabine;   Drug: Exemestane;   Drug: Fulvestrant
Sponsors:   Spanish Breast Cancer Research Group;   Pfizer;   AstraZeneca
Completed

Tue, 07 Jan 2014 12:00:00 EST

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Conditions:   Breast Adenocarcinoma;   HER2/Neu Negative;   Locally Advanced Breast Carcinoma;   Metastatic Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
Interventions:   Drug: Entinostat;   Drug: Exemestane;   Drug: Goserelin;   Drug: Goserelin Acetate;   Other: Placebo Administration;   Other: Quality-of-Life Assessment
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Wed, 16 Apr 2014 12:00:00 EDT

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

Conditions:   Estrogen Receptor Positive Breast Cancer;   Progesterone Receptor Positive Tumor;   Recurrent Breast Carcinoma;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage IIA Breast Cancer;   Stage IIB Breast Cancer;   Stage IIIA Breast Cancer
Interventions:   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Procedure: Oophorectomy;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Tamoxifen;   Drug: Triptorelin
Sponsors:   International Breast Cancer Study Group;   Breast International Group;   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   NSABP Foundation Inc;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   Southwest Oncology Group
Active, not recruiting

Thu, 07 Aug 2003 12:00:00 EDT

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Condition:   Breast Neoplasms
Interventions:   Drug: E7090;   Drug: Fulvestrant;   Drug: Exemestane
Sponsor:   Eisai Co., Ltd.
Recruiting

Thu, 01 Oct 2020 12:00:00 EDT

Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: tamoxifen citrate;   Procedure: adjuvant therapy
Sponsor:   Cancer Research Campaign Clinical Trials Centre
Completed

Mon, 27 Jan 2003 12:00:00 EST

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab

Conditions:   Breast Cancer Recurrent;   HER2/Neu-negative Carcinoma of Breast;   Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions:   Drug: Bevacizumab;   Drug: Capecitabine;   Drug: Everolimus;   Drug: Exemestane;   Other: Patient questionaires
Sponsors:   iOMEDICO AG;   Arbeitsgemeinschaft fur Internistische Onkologie;   Novartis Pharmaceuticals
Completed

Thu, 25 Sep 2014 12:00:00 EDT

Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Enobosarm & Abemaciclib Combo;   Drug: non-steroidal AI, or steroidal AI (exemestane with or without everolimus) or Fulvestrant
Sponsor:   Veru Inc.
Not yet recruiting

Mon, 04 Oct 2021 12:00:00 EDT

MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: MSK-2206;   Drug: Exemestane;   Drug: Goserelin
Sponsor:   Vanderbilt-Ingram Cancer Center
Withdrawn

Mon, 15 Nov 2010 12:00:00 EST

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Procedure: Therapeutic Conventional Surgery
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Completed

Thu, 15 Dec 2005 12:00:00 EST

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Enobosarm;   Drug: Exemestane
Sponsor:   Veru Inc.
Recruiting

Mon, 03 May 2021 12:00:00 EDT

Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Condition:   Advanced or Recurrent Breast Cancer
Interventions:   Drug: Entinostat;   Drug: Entinostat(Placebo);   Drug: Exemestane
Sponsor:   Kyowa Kirin Co., Ltd.
Active, not recruiting

Mon, 25 Sep 2017 12:00:00 EDT

Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer

Condition:   Hormone Receptor Positive Breast Cancer
Interventions:   Drug: Everolimus;   Drug: Letrozole;   Drug: Exemestane;   Drug: Alcohol-free dexamethasone mouth rinse
Sponsor:   Novartis Pharmaceuticals
Completed

Wed, 03 Oct 2012 12:00:00 EDT

Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: exemestane;   Drug: fulvestrant
Sponsor:   Institute of Cancer Research, United Kingdom
Unknown status

Tue, 15 Nov 2005 12:00:00 EST

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Drug: tamoxifen citrate
Sponsor:   Gruppo Italiano Mammella (GIM)
Active, not recruiting

Mon, 08 Oct 2007 12:00:00 EDT

Pharmacology of Adjuvant Hormonotherapy in Breast Cancer

Condition:   Hormono-depending Adjuvant Breast Cancer
Intervention:   Drug: Tamoxifen, Letrozole, Anastrozole or Exemestane
Sponsor:   Institut Claudius Regaud
Completed

Thu, 20 May 2010 12:00:00 EDT

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

Condition:   Neoplasms
Interventions:   Drug: Everolimus;   Drug: Exemestane;   Drug: BI 836845
Sponsor:   Boehringer Ingelheim
Active, not recruiting

Mon, 28 Apr 2014 12:00:00 EDT

Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients

Conditions:   Breast Cancer;   Pain;   Arthralgia
Interventions:   Drug: Anastrozole;   Drug: exemestane;   Drug: letrozole
Sponsors:   Lynn Henry;   Damon Runyon Cancer Research Foundation
Completed

Tue, 19 Mar 2013 12:00:00 EDT

500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI

Condition:   Breast Cancer
Intervention:  
Sponsor:   Fudan University
Completed

Thu, 04 Oct 2018 12:00:00 EDT

Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Tamoxifen, Letrozole , Anastrozole, Exemestane
Sponsor:   Institut Claudius Regaud
Completed

Wed, 06 Jun 2012 12:00:00 EDT

Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer

Conditions:   Breast Cancer;   Arthralgia;   Obesity
Interventions:   Drug: anastrozole, letrozole, exemestane;   Drug: Tamoxifen
Sponsor:   University of Michigan Rogel Cancer Center
Completed

Thu, 11 Jul 2013 12:00:00 EDT

Exemestane With or Without ATN-224 in Treating Postmenopausal Women With Recurrent or Advanced Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: SOD1 inhibitor ATN-224;   Drug: exemestane;   Genetic: protein expression analysis;   Genetic: proteomic profiling;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsor:   Cancer Research UK
Terminated

Thu, 08 May 2008 12:00:00 EDT

Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02

Conditions:   Breast Cancer;   Fatigue;   Sleep Disorders
Interventions:   Drug: Tamoxifen;   Drug: triptorelin;   Drug: Exemestane
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Breast Cancer Trials, Australia and New Zealand;   Cancer and Leukemia Group B
Completed

Wed, 16 Apr 2008 12:00:00 EDT

CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Anastrozole or Letrozole or Exemestane
Sponsors:   IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy;   Clinical Research Technology S.r.l.
Recruiting

Wed, 28 Sep 2016 12:00:00 EDT

Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer

Conditions:   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions:   Drug: exemestane;   Procedure: adjuvant therapy;   Procedure: aromatase inhibition;   Procedure: conventional surgery;   Procedure: endocrine therapy;   Procedure: hormone therapy;   Procedure: neoadjuvant therapy;   Procedure: surgery
Sponsors:   Robert H. Lurie Cancer Center;   National Cancer Institute (NCI)
Withdrawn

Thu, 08 Apr 2004 12:00:00 EDT

A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)

Condition:   Breast Cancer
Interventions:   Drug: ridaforolimus + dalotuzumab;   Drug: exemestane;   Drug: ridaforolimus;   Drug: dalotuzumab
Sponsor:   Merck Sharp & Dohme Corp.
Completed

Thu, 04 Nov 2010 12:00:00 EDT

Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

Condition:   Advanced Breast Cancer
Interventions:   Drug: Dexamethasone based mouthwash;   Drug: Everolimus;   Drug: Exemestane
Sponsor:   Novartis Pharmaceuticals
Completed

Fri, 21 Feb 2014 12:00:00 EST

Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Hemay022+exemestane;   Drug: Hemay022+letrozole;   Drug: Hemay022+ fulvestrant
Sponsor:   Tianjin Hemay Pharmaceutical Co.,Ltd
Recruiting

Thu, 12 Oct 2017 12:00:00 EDT

The Effects of Short-term Preoperative Treatment With Hormonal Therapy on Gene Profiles in Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Tamoxifen Citrate;   Drug: Letrozole;   Drug: Exemestane;   Diagnostic Test: Blueprint;   Diagnostic Test: Mammaprint
Sponsors:   Johns Hopkins University;   Agendia
Recruiting

Wed, 16 Oct 2019 12:00:00 EDT

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Conditions:   Breast Ductal Carcinoma In Situ;   Invasive Breast Carcinoma;   Multicentric Breast Carcinoma;   Multifocal Breast Carcinoma;   Synchronous Bilateral Breast Carcinoma
Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Drug: Systemic Chemotherapy;   Drug: Tamoxifen Citrate
Sponsor:   National Cancer Institute (NCI)
Active, not recruiting

Fri, 07 Jan 2011 12:00:00 EST

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Condition:   Stage I Breast Cancer
Interventions:   Other: Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane);   Drug: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Sponsors:   NRG Oncology;   National Cancer Institute (NCI)
Not yet recruiting

Wed, 21 Apr 2021 12:00:00 EDT

Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Everolimus;   Drug: Everolimus-placebo
Sponsors:   German Breast Group;   Novartis
Terminated

Wed, 23 Jan 2013 12:00:00 EST

Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Drug: tamoxifen citrate
Sponsor:   Centre Oscar Lambret
Unknown status

Tue, 05 May 2009 12:00:00 EDT

Effects of Exemestane on Bone Strength

Conditions:   Osteoporosis;   Breast Cancer
Intervention:  
Sponsors:   University Health Network, Toronto;   Canadian Breast Cancer Research Alliance
Unknown status

Tue, 15 Jun 2010 12:00:00 EDT

Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients

Conditions:   FGFR Inhibition, Pharmacokinetics, Biomarkers;   ER+ Breast Cancer
Interventions:   Drug: AZD4547;   Drug: Exemestane;   Drug: Placebo;   Drug: Fulvestrant
Sponsor:   AstraZeneca
Completed

Thu, 16 Sep 2010 12:00:00 EDT

Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer

Conditions:   Lung Cancer;   Non Small Cell Lung Cancer (NSCLC);   Breast Cancer;   Estrogen Receptor Breast Cancer
Interventions:   Drug: entinostat;   Drug: Erlotinib;   Drug: Exemestane
Sponsor:   Syndax Pharmaceuticals
Completed

Wed, 09 May 2012 12:00:00 EDT

Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Drug: sorafenib tosylate;   Other: placebo
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Terminated

Fri, 14 Dec 2007 12:00:00 EST

Neoadjuvant Endocrine Therapy Tolerance in Geriatric Early Stage ER+ Breast Cancer

Condition:   Breast Cancer Female
Interventions:   Drug: tamoxifen, letrozole, anastrozole, or exemestane;   Behavioral: Patient reported outcomes
Sponsor:   Trish Millard, MD
Recruiting

Mon, 17 Feb 2020 12:00:00 EST

A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer

Conditions:   Postmenopause;   Breast Cancer
Intervention:  
Sponsor:   AstraZeneca
Completed

Wed, 28 Jul 2010 12:00:00 EDT

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: enzalutamide;   Drug: anastrozole;   Drug: exemestane;   Drug: fulvestrant
Sponsors:   Pfizer;   Astellas Pharma Inc;   Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Completed

Fri, 11 May 2012 12:00:00 EDT

Study of LY3484356 Versus Hormone Therapy, in Participants With Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer

Conditions:   Breast Neoplasms;   Neoplasm Metastasis
Interventions:   Drug: LY3484356;   Drug: Exemestane;   Drug: Fulvestrant
Sponsor:   Eli Lilly and Company
Not yet recruiting

Fri, 23 Jul 2021 12:00:00 EDT

PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Palbociclib 125mg;   Drug: Aromatase Inhibitors;   Drug: Fulvestrant Injectable Product
Sponsors:   UNICANCER;   Pfizer
Active, not recruiting

Tue, 14 Mar 2017 12:00:00 EDT

Premenopausal Endocrine Responsive Chemotherapy Trial

Condition:   Breast Cancer
Interventions:   Drug: chemotherapy;   Drug: exemestane;   Drug: tamoxifen;   Drug: triptorelin;   Procedure: oophorectomy;   Procedure: ovarian irradiation
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Breast International Group
Terminated

Thu, 07 Aug 2003 12:00:00 EDT

Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Elacestrant;   Drug: Standard of Care
Sponsor:   Radius Pharmaceuticals, Inc.
Active, not recruiting

Wed, 19 Dec 2018 12:00:00 EST

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Conditions:   Breast Cancer;   Hormone Receptor Positive Tumor
Interventions:   Drug: Durvalumab;   Drug: Anastrozole 1mg;   Drug: Letrozole 2.5mg;   Drug: Exemestane 25 MG
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   AstraZeneca
Active, not recruiting

Thu, 14 Mar 2019 12:00:00 EDT

Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor

Condition:   Metastatic Breast Cancer
Intervention:   Procedure: Biopsy
Sponsors:   UNICANCER;   Novartis;   Fondation ARC
Active, not recruiting

Thu, 14 May 2015 12:00:00 EDT

Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients

Condition:   Breast Cancer
Interventions:   Drug: Exemestane;   Drug: Letrozole;   Drug: Anastrozole
Sponsor:   Chinese Academy of Medical Sciences
Unknown status

Fri, 06 May 2016 12:00:00 EDT

Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients

Condition:   Breast Cancer Metastatic
Interventions:   Drug: Everolimus;   Drug: Aromatase Inhibitors
Sponsors:   Istituto Oncologico Veneto IRCCS;   University of Padova
Completed

Thu, 30 Jul 2015 12:00:00 EDT

Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant

Conditions:   Breast Cancer;   Hormone Receptor Positive Tumor;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions:   Drug: Palbociclib;   Drug: Letrozole;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Fulvestrant
Sponsors:   iOMEDICO AG;   Pfizer
Active, not recruiting

Fri, 09 Sep 2016 12:00:00 EDT

Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02

Conditions:   Breast Cancer;   Osteoporosis
Interventions:   Other: laboratory biomarker analysis;   Procedure: dual x-ray absorptiometry
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Breast International Group
Active, not recruiting

Fri, 21 Aug 2009 12:00:00 EDT

Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02

Condition:   Breast Cancer
Intervention:   Other: gas chromatography / tandem mass spectometry
Sponsor:   International Breast Cancer Study Group
Completed

Fri, 11 Sep 2009 12:00:00 EDT

ExclUsive endocRine Therapy Or Partial Breast Irradiation for Women Aged ≥70 Years Early Stage Breast Cancer

Condition:   Breast Cancer
Interventions:   Radiation: Partial Breast Irradiation (PBI);   Drug: Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen
Sponsors:   Azienda Ospedaliero-Universitaria Careggi;   University of Florence
Recruiting

Tue, 22 Oct 2019 12:00:00 EDT

Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Capecitabine;   Drug: Aromatase Inhibitor
Sponsor:   Sun Yat-sen University
Recruiting

Tue, 10 May 2016 12:00:00 EDT

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Conditions:   Breast Cancer;   Invasive Breast Cancer
Interventions:   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane;   Drug: Tamoxifen
Sponsor:   Medical College of Wisconsin
Active, not recruiting

Mon, 17 Jul 2017 12:00:00 EDT

Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: capecitabine;   Drug: hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
Sponsor:   The Netherlands Cancer Institute
Terminated

Mon, 26 May 2008 12:00:00 EDT

Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3

Conditions:   Breast Cancer;   Osteoporosis
Interventions:   Other: biologic sample preservation procedure;   Procedure: dual x-ray absorptometry
Sponsor:   NCIC Clinical Trials Group
Completed

Mon, 02 Jun 2008 12:00:00 EDT

Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer

Conditions:   Breast Cancer;   Endocrine Therapy;   Endocrine Therapy Adverse Reaction;   Vitamin D Deficiency;   Nutrition Disorders;   Obesity
Interventions:   Drug: Tamoxifen;   Drug: Exemestane;   Drug: Anastrozole;   Diagnostic Test: Basal;   Diagnostic Test: Recurrence
Sponsors:   Instituto Jalisciense de Cancerologia;   University of Guadalajara
Recruiting

Fri, 15 May 2020 12:00:00 EDT

Aromatase Inhibitor Clinical Trial

Condition:   Breast Cancer
Intervention:   Drug: pharmacodynamic analysis
Sponsors:   National Institute of General Medical Sciences (NIGMS);   Indiana University School of Medicine;   Office of Research on Women's Health (ORWH);   National Institute of Environmental Health Sciences (NIEHS)
Unknown status

Thu, 29 Sep 2005 12:00:00 EDT

Quality of Life in Postmenopausal Women Who Are Receiving Either Exemestane or Anastrozole With or Without Celecoxib for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

Condition:   Breast Cancer
Intervention:   Procedure: quality-of-life assessment
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   NCIC Clinical Trials Group
Completed

Wed, 08 Sep 2004 12:00:00 EDT

Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: AI plus Dimethyldiguanide;   Drug: Aromatase Inhibitor
Sponsor:   Xichun Hu
Completed

Tue, 31 Jul 2012 12:00:00 EDT

Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy

Condition:   HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
Interventions:   Drug: Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant;   Drug: Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy
Sponsor:   Novartis Pharmaceuticals
Active, not recruiting

Thu, 28 Apr 2016 12:00:00 EDT

Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)

Condition:   Low Grade Endometrial Stromal Sarcoma
Intervention:   Drug: Aromatase Inhibitors
Sponsor:   Centre Leon Berard
Recruiting

Fri, 10 Aug 2018 12:00:00 EDT

Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: MK-2206;   Drug: Exemestane;   Drug: Goserelin
Sponsor:   Vanderbilt-Ingram Cancer Center
Withdrawn

Mon, 15 Nov 2010 12:00:00 EST

Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not

Condition:   Breast Cancer
Interventions:   Drug: Tamoxifen,;   Drug: Exemestane;   Drug: Anastrozole;   Drug: Letrozole
Sponsor:   Institut Claudius Regaud
Completed

Wed, 14 Mar 2012 12:00:00 EDT

A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).

Condition:   Metastatic Breast Cancer
Intervention:   Drug: Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen)
Sponsors:   German Breast Group;   Pfizer;   AMS Advanced Medical Services GmbH
Recruiting

Tue, 28 Nov 2017 12:00:00 EST

Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer

Condition:   Breast Neoplasms
Intervention:   Drug: Endocrine therapy
Sponsor:   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Recruiting

Wed, 17 Jul 2019 12:00:00 EDT

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

Conditions:   Breast Cancer;   Cancer of Breast;   Breast Neoplasms;   Cancer of the Breast
Interventions:   Behavioral: FACT-B;   Drug: Goserelin;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Fulvestrant;   Drug: Tamoxifen;   Other: Archived tissue collection
Sponsors:   Washington University School of Medicine;   Genomic Health®, Inc.
Recruiting

Fri, 19 Jun 2015 12:00:00 EDT

Dendritic Cell Based Therapy for Breast Cancer Patients

Condition:   Breast Cancer
Interventions:   Biological: DC vaccine;   Drug: aromatase inhibitor
Sponsor:   Inge Marie Svane
Withdrawn

Thu, 09 Jul 2009 12:00:00 EDT

Changes in Breast Density and Blood Hormone Levels in Postmenopausal Women Receiving Anastrozole or Exemestane for Breast Cancer

Condition:   Breast Cancer
Interventions:   Genetic: polymorphism analysis;   Other: high performance liquid chromatography;   Other: laboratory biomarker analysis;   Procedure: radiomammography
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
Completed

Wed, 15 Aug 2007 12:00:00 EDT

Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients

Condition:   Breast Cancer
Interventions:   Drug: Aromatase Inhibitors (Arimidex);   Drug: Tamoxifen;   Procedure: SOB;   Drug: FAC;   Drug: Aromatase Inhibitors (Femara);   Drug: Aromatase Inhibitors (Aromasin)
Sponsor:   Dharmais National Cancer Center Hospital
Completed

Fri, 16 Dec 2016 12:00:00 EST

Effect of Endocrine Therapy Duration on Clinical Outcome of Patients With HR+ Intraductal Carcinoma of the Breast

Condition:   Breast Cancer
Interventions:   Drug: Tamoxifen;   Drug: Toremifene;   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane
Sponsors:   First Hospital of China Medical University;   The First Hospital of Jilin University;   Second Hospital of Jilin University;   Jilin Provincial Tumor Hospital;   The Affiliated Zhongshan Hospital of Dalian University;   The First Affiliated Hospital of Dalian Medical University;   China-Japan Union Hospital, Jilin University;   The Second Affiliated Hospital of Dalian Medical University;   The Fifth People's Hospital of Shenyang;   General Hospital of Benxi Steel & Iron (Group) Co., Ltd;   Affiliated Hospital of Hebei University of Engineering;   Fourth People's Hospital of Shenyang
Active, not recruiting

Mon, 14 Dec 2020 12:00:00 EST

Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer

Condition:   Breast Cancer Metastatic
Interventions:   Drug: Amcenestrant;   Drug: Fulvestrant;   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane;   Drug: Tamoxifen
Sponsor:   Sanofi
Recruiting

Fri, 16 Aug 2019 12:00:00 EDT

Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients

Condition:   Breast Cancer
Interventions:   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Triptorelin;   Drug: Exemestane;   Drug: Nivolumab
Sponsors:   Istituto Oncologico Veneto IRCCS;   University of Padova
Completed

Wed, 09 Dec 2020 12:00:00 EST

Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Bicalutamide;   Drug: Aromatase Inhibitor
Sponsors:   Xu fei;   Sun Yat-sen University
Unknown status

Wed, 21 Sep 2016 12:00:00 EDT

NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer

Condition:   Breast Neoplasms
Interventions:   Drug: Exemestane;   Drug: Letrozole;   Drug: Anastrozole;   Drug: Leuprolide Acetate;   Drug: Pertuzumab;   Drug: Trastuzumab
Sponsor:   Midwestern Regional Medical Center
Unknown status

Wed, 24 Feb 2016 12:00:00 EST

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Conditions:   Estrogen Receptor Negative;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Negative;   Progesterone Receptor Positive;   Stage IV Breast Cancer;   Triple-Negative Breast Carcinoma
Interventions:   Drug: Anastrozole;   Drug: Doxorubicin Hydrochloride;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Biological: Pembrolizumab
Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI);   Merck Sharp & Dohme Corp.
Active, not recruiting

Thu, 07 Jan 2016 12:00:00 EST

ER Reactivation Therapy for Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: 17B-estradiol;   Drug: Letrozole;   Drug: Anastrozole;   Drug: Exemestane
Sponsor:   Dartmouth-Hitchcock Medical Center
Recruiting

Mon, 14 Jul 2014 12:00:00 EDT

Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer

Condition:   Breast Cancer Metastatic
Interventions:   Drug: Ribociclib;   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane;   Drug: Fulvestrant
Sponsor:   German Breast Group
Recruiting

Thu, 14 Jun 2018 12:00:00 EDT

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy

Conditions:   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions:   Drug: vorinostat;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Radiation: F-18 16 alpha-fluoroestradiol;   Procedure: positron emission tomography;   Drug: anastrozole;   Drug: letrozole;   Drug: exemestane;   Genetic: gene expression analysis
Sponsors:   University of Washington;   National Cancer Institute (NCI)
Completed

Wed, 30 Jun 2010 12:00:00 EDT

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Conditions:   HER2/Neu Negative;   Invasive Breast Carcinoma;   Postmenopausal;   Stage 0 Breast Cancer;   Stage IA Breast Cancer
Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tamoxifen Citrate;   Drug: Toremifene Citrate
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Withdrawn

Thu, 03 Aug 2017 12:00:00 EDT

To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy

Condition:   Breast Cancer
Interventions:   Drug: Palbociclib;   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane;   Drug: Fulvestrant
Sponsor:   Fondazione Sandro Pitigliani
Completed

Tue, 15 Sep 2015 12:00:00 EDT

Breast Cancer, Sexuality and Black Cohosh

Condition:   Sexuality
Interventions:   Behavioral: WHOQOL questionnaire;   Behavioral: FSFI questionnaire;   Behavioral: kupperman scale;   Drug: Cimicifuga racemosa;   Drug: tamoxifen;   Drug: exemestane
Sponsor:   Irmandade da Santa Casa de Misericordia de Sao Paulo
Unknown status

Wed, 10 Jun 2015 12:00:00 EDT

Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis

Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Metastatic Breast Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Progesterone Receptor Positive;   Prognostic Stage IV Breast Cancer AJCC v8
Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Drug: Fulvestrant;   Drug: Letrozole;   Drug: Palbociclib;   Radiation: Radiation Therapy;   Drug: Tamoxifen
Sponsors:   Emory University;   Pfizer
Recruiting

Mon, 01 Oct 2018 12:00:00 EDT

Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca.

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Avastin;   Drug: Hormonal therapy
Sponsors:   University of Alabama at Birmingham;   Genentech, Inc.
Completed

Mon, 17 Oct 2005 12:00:00 EDT

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

Conditions:   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions:   Drug: vorinostat;   Drug: anastrozole;   Drug: letrozole;   Drug: exemestane;   Procedure: positron emission tomography;   Radiation: F-18 16 alpha-fluoroestradiol;   Radiation: fludeoxyglucose F 18;   Other: laboratory biomarker analysis
Sponsors:   University of Washington;   National Cancer Institute (NCI)
Completed

Fri, 02 Nov 2012 12:00:00 EDT

Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Paclitaxel;   Drug: Bevacizumab;   Drug: Letrozole;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Fulvestrant;   Drug: Goserelin;   Drug: leuprorelin;   Drug: LHRH Analogs + Aromatase inhibitors
Sponsors:   Japan Breast Cancer Research Group;   Chugai Pharmaceutical
Unknown status

Thu, 21 Nov 2013 12:00:00 EST

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Dovitinib;   Drug: Aromatase Inhibitors
Sponsors:   Georgetown University;   Novartis Pharmaceuticals
Terminated

Fri, 02 Dec 2011 12:00:00 EST

Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer

Conditions:   Breast Cancer Female;   HER2-positive Breast Cancer;   Hormone Receptor Positive Malignant Neoplasm of Breast;   Metastatic Breast Cancer;   Breast Diseases;   Hormone Receptor Positive Tumor
Interventions:   Drug: Pyrotinib;   Drug: Trastuzumab;   Drug: Aromatase Inhibitors
Sponsor:   Fuzhou General Hospital
Not yet recruiting

Thu, 12 Sep 2019 12:00:00 EDT

Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC

Conditions:   Breast Cancer Female;   HER2-positive Breast Cancer;   Hormone Receptor Positive Malignant Neoplasm of Breast;   Metastatic Breast Cancer;   Breast Diseases;   Hormone Receptor Positive Tumor
Interventions:   Drug: Pyrotinib;   Drug: Trastuzumab;   Drug: Aromatase inhibitor
Sponsor:   Peking Union Medical College Hospital
Not yet recruiting

Wed, 10 Apr 2019 12:00:00 EDT

A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer

Condition:   Breast Neoplasm
Interventions:   Drug: Megestrol Acetate 160Mg Tablet;   Drug: Anastrozole 1Mg Tablet;   Drug: Letrozole 2.5Mg Tablet;   Drug: Exemestane 25 MG;   Drug: Tamoxifen 20Mg Tablet;   Drug: Fulvestrant 50Mg Solution for Injection
Sponsors:   Instituto Nacional de Cancer, Brazil;   Cancer Research UK Cambridge Institute
Unknown status

Thu, 19 Jan 2017 12:00:00 EST

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Conditions:   Breast Adenocarcinoma;   Hormone Receptor Positive;   Stage IA Breast Cancer AJCC v7;   Stage IB Breast Cancer AJCC v7;   Stage IIA Breast Cancer AJCC v6 and v7;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage IIIB Breast Cancer AJCC v7
Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Tamoxifen Citrate
Sponsors:   National Cancer Institute (NCI);   American College of Surgeons;   Cancer and Leukemia Group B;   NSABP Foundation Inc;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   Southwest Oncology Group
Active, not recruiting

Mon, 03 Apr 2006 12:00:00 EDT

Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: exemestane;   Drug: letrozole;   Procedure: assessment of therapy complications
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Active, not recruiting

Tue, 22 Jul 2008 12:00:00 EDT

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

Condition:   Breast Cancer
Intervention:   Drug: Neratinib + endocrine therapy
Sponsor:   SOLTI Breast Cancer Research Group
Recruiting

Tue, 07 Jul 2020 12:00:00 EDT

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Active, not recruiting

Tue, 28 Aug 2012 12:00:00 EDT

T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With Metastatic, Unresectable, or Locoregionally Recurrent HER2- Negative Breast Cancer

Conditions:   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Prognostic Stage IV Breast Cancer AJCC v8;   Recurrent Breast Carcinoma
Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Drug: Fulvestrant;   Drug: Letrozole;   Drug: Paclitaxel;   Biological: Talimogene Laherparepvec;   Drug: Tamoxifen;   Drug: Nab paclitaxel;   Drug: Gemcitabine;   Drug: Carboplatin
Sponsors:   University of California, San Francisco;   Amgen
Recruiting

Tue, 12 Jun 2018 12:00:00 EDT

Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Capecitabine plus aromatase inhibitor;   Drug: A.I.
Sponsor:   Ain Shams University
Unknown status

Tue, 09 Jul 2019 12:00:00 EDT

FASN Inhibitor TVB-2640 and Trastuzumab in Combination With Paclitaxel or Endocrine Therapy for the Treatment of HER2 Positive Metastatic Breast Cancer

Conditions:   Advanced Breast Carcinoma;   HER2 Positive Breast Carcinoma;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Stage IV Breast Cancer AJCC v6 and v7
Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Drug: FASN Inhibitor TVB-2640;   Drug: Fulvestrant;   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Drug: Paclitaxel;   Biological: Trastuzumab
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting

Wed, 07 Jun 2017 12:00:00 EDT

First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.

Condition:   Breast Neoplasms
Intervention:   Drug: Palbociclib + endocrine therapy
Sponsor:   Pfizer
Recruiting

Tue, 23 Feb 2021 12:00:00 EST

A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)

Conditions:   Metastatic Breastcancer;   Estrogen Receptor Positive Breast Cancer;   Estrogen Receptor Negative Neoplasm;   Progesterone Receptor Positive Tumor;   Progesterone Receptor Negative Neoplasm;   Androgen Receptor Gene Overexpression
Intervention:   Drug: DHEA
Sponsor:   Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Terminated

Wed, 04 Dec 2013 12:00:00 EST

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

Condition:   Breast Cancer
Interventions:   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Exemestane;   Drug: Goserelin;   Drug: Carboplatin
Sponsors:   Spanish Breast Cancer Research Group;   Pfizer
Completed

Wed, 07 Feb 2007 12:00:00 EST

Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure

Conditions:   Breast Cancer;   Estrogen Receptor Positive Tumor;   Menopause;   Hormone Antagonist
Interventions:   Drug: Immune-attractant;   Drug: Durvalumab;   Procedure: Biopsy
Sponsors:   UNICANCER;   Breast International Group
Completed

Tue, 20 Dec 2016 12:00:00 EST

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Palbociclib;   Drug: Aromatase Inhibitor
Sponsors:   Dana-Farber Cancer Institute;   Pfizer
Completed

Mon, 20 Jan 2014 12:00:00 EST

Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Everolimus;   Drug: Exemestane;   Drug: Tamoxifen;   Drug: Fulvestrant;   Drug: Anastrozole;   Drug: Letrozole;   Drug: Toremifine
Sponsors:   SCRI Development Innovations, LLC;   Novartis
Completed

Mon, 17 Nov 2014 12:00:00 EST

Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Conditions:   Postmenopausal Women;   Locally Advanced Metastatic Breast Cancer;   Metastatic Breast Cancer
Interventions:   Drug: Everolimus;   Drug: Letrozole
Sponsor:   Novartis Pharmaceuticals
Completed

Mon, 01 Nov 2010 12:00:00 EDT

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

Conditions:   ER+ Breast Cancer;   HER2-negative Breast Cancer
Interventions:   Drug: Palbociclib 125Mg Tab;   Drug: Fulvestrant injection;   Drug: Tamoxifen;   Drug: Letrozole;   Drug: Exemestane;   Drug: Anastrozole
Sponsors:   Royal Marsden NHS Foundation Trust;   Pfizer;   AstraZeneca;   Institute of Cancer Research, United Kingdom;   UNICANCER;   Gustave Roussy, Cancer Campus, Grand Paris
Not yet recruiting

Mon, 02 Aug 2021 12:00:00 EDT

Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Capecitabine;   Drug: aromatase Inhibitors (AIs)
Sponsor:   Fudan University
Unknown status

Fri, 16 Aug 2013 12:00:00 EDT

Omega-3 Fatty Acids in Preventing Joint Symptoms in Patients With Stage I-III Breast Cancer Receiving Anastrozole, Exemestane, or Letrozole

Conditions:   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions:   Dietary Supplement: omega-3 fatty acid supplement;   Other: Placebo;   Other: Clinical assessments;   Other: Assessment of therapy complications;   Procedure: Magnetic Resonance Imaging;   Procedure: Correlative/special studies
Sponsors:   Ohio State University Comprehensive Cancer Center;   Cancer and Leukemia Group B
Active, not recruiting

Wed, 23 Nov 2011 12:00:00 EST

Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole

Condition:   Breast Cancer
Intervention:   Procedure: mammography
Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   NCIC Clinical Trials Group
Completed

Fri, 21 Apr 2006 12:00:00 EDT

Acupuncture in Reducing Muscle and Bone Symptoms in Women Receiving Letrozole, Exemestane, or Anastrozole for Stage 0, Stage I, Stage II, or Stage III Breast Cancer

Conditions:   Anxiety Disorder;   Breast Cancer;   Depression;   Fatigue;   Hot Flashes;   Pain;   Sleep Disorders
Interventions:   Procedure: acupuncture therapy;   Procedure: sham intervention
Sponsors:   University of Maryland, College Park;   National Cancer Institute (NCI);   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Completed

Mon, 24 Mar 2008 12:00:00 EDT

Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Palbociclib;   Drug: Endocrine therapy (non IMP)
Sponsor:   MedSIR
Completed

Mon, 12 Jun 2017 12:00:00 EDT

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: cyclophosphamide;   Drug: exemestane;   Drug: letrozole;   Drug: methotrexate;   Drug: prednisolone
Sponsor:   National Cancer Centre, Singapore
Unknown status

Mon, 02 Jun 2008 12:00:00 EDT

Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients

Condition:   Breast Cancer
Interventions:   Drug: Neoadjuvant endocrine therapy;   Drug: Neoadjuvant chemotherapy
Sponsor:   Ruijin Hospital
Terminated

Tue, 25 Aug 2015 12:00:00 EDT

Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases

Conditions:   Early-Stage Breast Carcinoma;   Estrogen Receptor Positive Tumor
Interventions:   Drug: Paclitaxel;   Drug: Tamoxifen + Palbociclib;   Drug: Aromatase Inhibitor + Palbociclib;   Drug: Goserelin + Aromatase Inhibitor + Palbociclib
Sponsor:   Thomas Hatschek
Active, not recruiting

Fri, 13 Nov 2015 12:00:00 EST

Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC

Conditions:   Breast Cancer;   Invasive Breast Cancer;   ER-Negative PR-Negative HER2-Negative Breast Cancer
Intervention:   Drug: Entinostat
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   Syndax Pharmaceuticals;   National Cancer Institute (NCI)
Terminated

Tue, 05 Dec 2017 12:00:00 EST

Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial

Conditions:   Breast Cancer;   Osteoporosis
Interventions:   Dietary Supplement: calcium carbonate;   Dietary Supplement: calcium citrate;   Dietary Supplement: cholecalciferol;   Drug: alendronate sodium;   Drug: calcium gluconate;   Drug: risedronate sodium;   Other: laboratory biomarker analysis;   Procedure: dual x-ray absorptometry
Sponsors:   NCIC Clinical Trials Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   Southwest Oncology Group
Completed

Thu, 20 Jul 2006 12:00:00 EDT

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

Conditions:   HER-2 Positive Breast Cancer;   Estrogen Receptor Positive Breast Cancer
Interventions:   Drug: palbociclib;   Drug: trastuzumab;   Drug: pertuzumab;   Drug: letrozole;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Fulvestrant
Sponsors:   Alliance Foundation Trials, LLC.;   Pfizer;   German Breast Group;   Fondazione Michelangelo;   PrECOG, LLC.;   Breast Cancer Trials, Australia and New Zealand;   Syneos Health;   SOLTI Breast Cancer Research Group;   UNICANCER
Active, not recruiting

Fri, 28 Oct 2016 12:00:00 EDT

Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer

Condition:   ER Positive, HER2 Negative Breast Cancer Neoplasms
Intervention:  
Sponsors:   KU Leuven;   Novartis
Unknown status

Tue, 23 Aug 2016 12:00:00 EDT

Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake

Condition:   Breast Cancer
Intervention:   Genetic: Polygenic Risk Score
Sponsors:   Mayo Clinic;   CancerCare Manitoba
Completed

Fri, 07 Aug 2015 12:00:00 EDT

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

Condition:   Breast Cancer Stage IV
Interventions:   Drug: Palbociclib;   Drug: Ribociclib;   Drug: Abemaciclib;   Drug: Letrozole;   Drug: Anastrozole;   Drug: Tamoxifen;   Drug: Fulvestrant;   Drug: Exemestane;   Drug: Alpelisib
Sponsor:   Blokhin's Russian Cancer Research Center
Recruiting

Wed, 21 Apr 2021 12:00:00 EDT

Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Endocrine therapy combined with trastuzumab;   Drug: Chemotherapy combined with trastuzumab
Sponsor:   Sun Yat-sen University
Completed

Wed, 25 Sep 2013 12:00:00 EDT

Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: TOL2506;   Drug: Tamoxifen;   Drug: Letrozole Tablets;   Drug: Anastrozole Tablets;   Drug: Exemestane Tablets
Sponsor:   Tolmar Inc.
Recruiting

Fri, 28 May 2021 12:00:00 EDT

Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: exemestane;   Drug: fulvestrant;   Drug: lapatinib ditosylate;   Drug: letrozole;   Other: placebo
Sponsor:   Gruppo Italiano Mammella (GIM)
Unknown status

Mon, 02 Jun 2008 12:00:00 EDT

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Ribociclib;   Drug: Adjuvant endocrine therapy;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Completed

Mon, 13 Mar 2017 12:00:00 EDT

A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread

Condition:   Breast Neoplasms
Interventions:   Drug: LY2835219;   Drug: Letrozole;   Drug: Anastrozole;   Drug: Tamoxifen;   Drug: Exemestane;   Drug: Everolimus;   Drug: Trastuzumab;   Drug: LY3023414;   Drug: Fulvestrant;   Drug: Pertuzumab;   Drug: Loperamide;   Drug: Endocrine therapy
Sponsor:   Eli Lilly and Company
Active, not recruiting

Thu, 06 Feb 2014 12:00:00 EST

Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors

Conditions:   Early-Stage Breast Carcinoma;   Hormone Receptor Positive Tumor
Interventions:   Drug: Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin;   Drug: Palbociclib
Sponsor:   Thomas Hatschek
Active, not recruiting

Fri, 30 Oct 2015 12:00:00 EDT

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

Condition:   Breast Cancer Recurrent
Interventions:   Drug: Palbociclib 125mg;   Drug: Standard endocrine therapy
Sponsors:   International Breast Cancer Study Group;   Pfizer
Recruiting

Tue, 29 Jan 2019 12:00:00 EST

Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

Condition:   Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Interventions:   Drug: MEDI-573;   Drug: Aromatase Inhibitor
Sponsor:   MedImmune LLC
Completed

Wed, 05 Oct 2011 12:00:00 EDT

PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Intervention:   Drug: PTC299
Sponsors:   PTC Therapeutics;   United States Department of Defense
Completed

Mon, 30 Jul 2007 12:00:00 EDT

Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy

Condition:   Breast Neoplasm
Interventions:   Drug: Palbociclib;   Drug: Fulvestrant;   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane
Sponsors:   Palleos Healthcare GmbH;   WSG WOMEN´S HEALTHCARE STUDY GROUP;   Cankado Service GmbH;   Pfizer;   AGO-TraFo;   AGO-B;   Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V.
Active, not recruiting

Tue, 18 Jul 2017 12:00:00 EDT

Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)

Condition:   Early-stage Breast Cancer
Intervention:   Combination Product: Endocrine Therapy and Radiotherapy
Sponsor:   Ottawa Hospital Research Institute
Active, not recruiting

Tue, 14 May 2019 12:00:00 EDT

Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database

Condition:   Breast Cancer
Interventions:   Other: Sample collection;   Behavioral: Patient-reported outcomes
Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Susan G. Komen Breast Cancer Foundation
Active, not recruiting

Mon, 09 Sep 2013 12:00:00 EDT

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer

Conditions:   Estrogen Receptor-positive Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage I Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer
Interventions:   Drug: exemestane;   Drug: triptorelin pamoate;   Drug: capecitabine;   Drug: methotrexate;   Drug: vinorelbine tartrate;   Drug: paclitaxel;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
Sponsors:   University of Washington;   National Cancer Institute (NCI)
Terminated

Mon, 19 Sep 2005 12:00:00 EDT

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Condition:   Breast Neoplasms
Interventions:   Drug: Perjeta Injectable Product;   Drug: Herceptin;   Drug: Tamoxifen;   Drug: Paclitaxel;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane;   Drug: Leuprorelin acetate;   Drug: Goserelin;   Drug: Leuporelin acetate;   Diagnostic Test: Biopsy;   Procedure: Surgery
Sponsors:   Palleos Healthcare GmbH;   Roche Pharma AG;   WSG WOMEN´S HEALTHCARE STUDY GROUP;   Cankado Service GmbH
Active, not recruiting

Tue, 05 Sep 2017 12:00:00 EDT

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Condition:   Breast Neoplasms
Interventions:   Drug: Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody;   Drug: Bevacizumab;   Drug: Entinostat;   Drug: Exemestane;   Drug: Fulvestrant;   Drug: Ipatasertib;   Drug: Tamoxifen;   Drug: Abemaciclib
Sponsor:   Hoffmann-La Roche
Recruiting

Tue, 12 Sep 2017 12:00:00 EDT

Pharmacogenetics of Anastrozole in Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Stage I, Stage II, or Stage III Breast Cancer

Condition:   Breast Cancer
Interventions:   Genetic: Single nucleotide polymorphism (SNP);   Other: high performance liquid chromatography;   Other: measurements by DXA;   Other: questionnaire administration
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Completed

Mon, 30 Jan 2006 12:00:00 EST

Detect V / CHEVENDO (Chemo vs. Endo)

Condition:   Metastatic Breast Cancer
Interventions:   Drug: pertuzumab;   Drug: Trastuzumab;   Drug: Capecitabine;   Drug: Paclitaxel;   Drug: Vinorelbine;   Drug: Docetaxel;   Drug: Exemestane;   Drug: Letrozole;   Drug: Anastrozole;   Drug: Fulvestrant;   Drug: Ribociclib;   Drug: nab-Paclitaxel;   Drug: eribulin;   Drug: leuprorelin;   Drug: goserelin
Sponsors:   Prof. W. Janni;   Roche Pharma AG;   Novartis Pharmaceuticals;   Eisai GmbH;   Celgene Corporation
Recruiting

Mon, 26 Jan 2015 12:00:00 EST

Oral Health in Breast Cancer Survivors on Aromatase Inhibitors

Conditions:   Periodontal Disease;   Quality of Life
Intervention:  
Sponsors:   University of Michigan;   National Institute of Dental and Craniofacial Research (NIDCR)
Completed

Wed, 26 Sep 2012 12:00:00 EDT

Breast Cancer Treatment Based on Organ-like Culture

Condition:   Breast Cancer Organoids
Interventions:   Drug: Trastuzumab;   Drug: Doxorubicin Hydrochloride;   Drug: Epirubicin hydrochloride;   Drug: Fluorouracil;   Drug: Paclitaxel;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Recombinant Human Endostatin;   Drug: Pirarubicin hydrochloride;   Drug: Pyrrolidine;   Drug: Ixabepilone;   Drug: Tamoxifen citrate;   Drug: Vinorelbine tartrate;   Drug: Carboplatin;   Drug: Methotrexate;   Drug: Eribulin mesylate;   Drug: Toremifene citrate;   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane;   Drug: Fulvestrant;   Drug: Olaparib;   Drug: Bevacizumab;   Drug: Apatinib mesylate;   Drug: Pattozumab;   Drug: Capecitabine;   Drug: Ear particles;   Drug: Aidi Injection;   Drug: Cyclophosphamide
Sponsor:   Xijing Hospital
Enrolling by invitation

Wed, 24 Apr 2019 12:00:00 EDT

Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

Conditions:   Breast Cancer Female;   Locally Advanced Breast Cancer;   Hormone Receptor Positive Malignant Neoplasm of Breast
Intervention:   Drug: Abemaciclib, durvalumab and aromatase inhibitor
Sponsors:   Alison Stopeck;   Eli Lilly and Company;   AstraZeneca
Withdrawn

Thu, 12 Sep 2019 12:00:00 EDT

Breast Cancer Women on Aromatase Inhibitors Treatment

Conditions:   Osteoporosis;   Osteoporosis Fracture;   Arthralgia Generalized
Intervention:   Drug: bisphosphonate
Sponsors:   Parc de Salut Mar;   Instituto de Salud Carlos III
Recruiting

Tue, 22 Jan 2019 12:00:00 EST

Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment

Condition:   Cancer
Intervention:  
Sponsors:   Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland;   Centre Hospitalier Universitaire Vaudois
Unknown status

Fri, 10 Jun 2011 12:00:00 EDT

Prediction of Everolimus-induced Interstitial Lung Disease

Condition:   Breast Neoplasms
Intervention:  
Sponsor:   Radboud University
Completed

Thu, 07 Nov 2013 12:00:00 EST

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Biological: IMC-A12 (cixutumumab);   Drug: tamoxifen;   Drug: Anastrozole;   Drug: Letrozole;   Drug: Exemestane;   Drug: Fulvestrant
Sponsor:   Eli Lilly and Company
Completed

Wed, 06 Aug 2008 12:00:00 EDT

Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT

Condition:   Breast Cancer
Interventions:   Procedure: Oral management;   Drug: Everolimus
Sponsors:   Comprehensive Support Project for Oncology Research;   Novartis Pharmaceuticals
Completed

Tue, 03 Mar 2015 12:00:00 EST

DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs

Conditions:   HER2-negative Metastatic Breast Cancer;   HER2-positive Circulating Tumor Cells
Interventions:   Drug: standard chemo- or endocrine therapy;   Drug: standard chemo- or endocrine therapy + Lapatinib
Sponsor:   Prof. W. Janni
Unknown status

Thu, 14 Jun 2012 12:00:00 EDT

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer

Condition:   Breast Cancer Metastatic
Interventions:   Drug: MCLA-128;   Drug: Trastuzumab;   Drug: Vinorelbine;   Drug: Endocrine therapy
Sponsor:   Merus N.V.
Active, not recruiting

Thu, 26 Oct 2017 12:00:00 EDT

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

Condition:   Breast Cancer
Intervention:   Drug: Everolimus
Sponsors:   Yale University;   Novartis Pharmaceuticals
Completed

Wed, 10 Sep 2014 12:00:00 EDT

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Conditions:   HER2-positive Breast Cancer;   Invasive Carcinoma of the Breast;   Breast Cancer;   Node Negative Breast Cancer;   Micrometastasis Breast Cancer;   Hormone Receptor Positive Breast Cancer
Interventions:   Combination Product: Pertuzumab+TRASTUZUMAB;   Drug: ADJUVANT ENDOCRINE THERAPY
Sponsors:   Dana-Farber Cancer Institute;   Genentech, Inc.
Recruiting

Wed, 30 Sep 2020 12:00:00 EDT

Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy

Condition:   Breast Cancer
Intervention:   Other: endocrine therapy
Sponsor:   Shengjing Hospital
Recruiting

Mon, 20 Jul 2020 12:00:00 EDT

Local Treatment in ER-positive/HER2-negative Oligo-metastatic Breast Cancer

Conditions:   Breast Cancer;   Recurrent Breast Cancer;   Stereotactic Body Radiotherapy;   Estrogen Receptor Positive Tumor;   Her2-negative Tumor;   Surgery
Interventions:   Procedure: Surgical resection;   Radiation: Stereotactic body radiotherapy;   Procedure: Radiofrequency ablation
Sponsors:   Gangnam Severance Hospital;   Severance Hospital;   Samsung Medical Center;   Asan Medical Center
Recruiting

Fri, 23 Nov 2018 12:00:00 EST

Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer

Condition:   Hormone Receptor-positive Breast Cancer
Intervention:   Drug: AI or TAM
Sponsor:   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not yet recruiting

Tue, 18 May 2021 12:00:00 EDT

Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients

Condition:   Breast Cancer
Intervention:  
Sponsor:   Fudan University
Completed

Thu, 31 May 2018 12:00:00 EDT

Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)

Condition:   Breast Cancer
Interventions:   Drug: capecitabine and trastuzumab;   Drug: endocrine therapy and trastuzumab
Sponsor:   Fudan University
Not yet recruiting

Tue, 12 May 2020 12:00:00 EDT

Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Capecitabine;   Drug: endocrine therapy
Sponsor:   Zhejiang Cancer Hospital
Recruiting

Sun, 02 Jul 2017 12:00:00 EDT

the Effect of Clomiphene Citrate Plus Estradiol Valerate Versus Letrozole on Endometrial Thickness and Pregnancy Rate in Infertile Women

Conditions:   Endometrial Thickness;   Pregnancy Rate
Interventions:   Drug: Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt;   Drug: letrozole (Femara; Novartis pharma AG, Basle, Switzerland)
Sponsor:   Laylay Mohammed Khalleefah Alhibshi
Completed

Fri, 06 Nov 2020 12:00:00 EST

Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

Conditions:   Urothelial Carcinoma;   Bladder Cancer;   Urinary Bladder Neoplasms
Interventions:   Drug: 75 approved agents;   Other: COXEN
Sponsor:   National Cancer Institute (NCI)
Completed

Thu, 02 Jun 2016 12:00:00 EDT

Dose EScalation Induction of EvERolimus

Conditions:   Breast Cancer;   Hormone Receptor Positive Tumor
Interventions:   Drug: 3 weeks Dose Induction of Everolimus;   Drug: 3 weeks Conventional Everolimus Dosing;   Drug: Open Label Phase with conventional 10mg Everolimus Dosing week 4-24;   Drug: Standard Care after 24 weeks
Sponsors:   German Breast Group;   Novartis
Recruiting

Thu, 12 Mar 2015 12:00:00 EDT

Oral Health and Oral Health-Related Quality of Life in Early Stage Breast Cancer Survivors

Conditions:   Breast Cancer;   Xerostomia
Intervention:  
Sponsor:   University of Michigan
Completed

Fri, 07 Jan 2011 12:00:00 EST

Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer

Condition:   Breast Cancer
Interventions:   Drug: Ribociclib;   Drug: Placebo;   Drug: Adjuvant endocrine therapy
Sponsor:   Novartis Pharmaceuticals
Withdrawn

Thu, 16 Mar 2017 12:00:00 EDT

Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer

Condition:   Neoplasms, Breast
Interventions:   Drug: Lapatinib;   Biological: Trastuzumab;   Drug: Aromatase Inhibitors (AIs)
Sponsor:   Novartis Pharmaceuticals
Terminated

Mon, 11 Aug 2014 12:00:00 EDT

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

Condition:   Early Breast Cancer
Interventions:   Drug: Giredestrant;   Drug: Endocrine Therapy of Physician's Choice;   Drug: LHRH Agonist
Sponsor:   Hoffmann-La Roche
Recruiting

Wed, 14 Jul 2021 12:00:00 EDT

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Conditions:   Breast Cancer;   Advanced Breast Cancer;   Metastatic Breast Cancer;   Endometrial Cancer
Interventions:   Drug: LY3484356;   Drug: Abemaciclib;   Drug: Everolimus;   Drug: Alpelisib;   Drug: Trastuzumab;   Drug: Aromatase Inhibitor (AI)
Sponsor:   Eli Lilly and Company
Recruiting

Fri, 06 Dec 2019 12:00:00 EST

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Condition:   Neoplasms, Breast
Interventions:   Drug: lapatinib;   Drug: trastuzumab;   Drug: Aromatase inhibitor
Sponsors:   Novartis Pharmaceuticals;   GlaxoSmithKline
Active, not recruiting

Mon, 12 Jul 2010 12:00:00 EDT

Study of Palbociclib and Trastuzumab With Endocrine Therapy in HER2-positive Metastatic Breast Cancer

Condition:   Metastatic Breast Cancer
Interventions:   Drug: Palbociclib;   Drug: Trastuzumab;   Drug: Endocrine therapy;   Drug: Chemotherapy;   Drug: Antibody-Drug Conjugates
Sponsor:   SOLTI Breast Cancer Research Group
Recruiting

Tue, 19 May 2015 12:00:00 EDT

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Condition:   Neoplasms, Breast
Interventions:   Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A;   Drug: Placebo;   Drug: Aromatase inhibitor;   Drug: 5-Fluorouracil;   Drug: Carboplatin AUC;   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Doxorubicin;   Drug: Epirubicin;   Drug: Paclitaxel;   Drug: Trastuzumab
Sponsor:   GlaxoSmithKline
Terminated

Wed, 13 Oct 2010 12:00:00 EDT